Validated Preclinical Mouse Model for Therapeutic Testing against Multidrug-Resistant Pseudomonas aeruginosa Strains

Jonathan M. Warawa, Xiaoxian Duan, Charles D. Anderson, Julie B. Sotsky, Daniel E. Cramer, Tia L. Pfeffer, Haixun Guo, Scott Adcock, Alexander J. Lepak, David R. Andes, Stacey A. Slone, Arnold J. Stromberg, Jon D. Gabbard, William E. Severson, Matthew B. Lawrenz

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The rise in infections caused by antibiotic-resistant bacteria is outpacing the development of new antibiotics. The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are a group of clinically important bacteria that have developed resistance to multiple antibiotics and are commonly referred to as multidrug resistant (MDR). The medical and research communities have recognized that, without new antimicrobials, infections by MDR bacteria will soon become a leading cause of morbidity and death. Therefore, there is an ever-growing need to expedite the development of novel antimicrobials to combat these infections. Toward this end, we set out to refine an existing mouse model of pulmonary Pseudomonas aeruginosa infection to generate a robust preclinical tool that can be used to rapidly and accurately predict novel antimicrobial efficacy. This refinement was achieved by characterizing the virulence of a panel of genetically diverse MDR P. aeruginosa strains in this model, by both 50% lethal dose (LD50) analysis and natural history studies. Further, we defined two antibiotic regimens (aztreonam and amikacin) that can be used as comparators during the future evaluation of novel antimicrobials, and we confirmed that the model can effectively differentiate between successful and unsuccessful treatments, as predicted by in vitro inhibitory data. This validated model represents an important tool in our arsenal to develop new therapies to combat MDR P. aeruginosa strains, with the ability to provide rapid preclinical evaluation of novel antimicrobials and support data from clinical studies during the investigational drug development process.

Original languageEnglish
JournalMicrobiology spectrum
Volume10
Issue number5
DOIs
StatePublished - Sep 2022

Bibliographical note

Publisher Copyright:
© 2022 Warawa et al.

Keywords

  • Pseudomonas aeruginosa
  • antibiotic testing
  • mouse models
  • pharmacokinetics
  • preclinical models

ASJC Scopus subject areas

  • Physiology
  • Ecology
  • General Immunology and Microbiology
  • Genetics
  • Microbiology (medical)
  • Cell Biology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Validated Preclinical Mouse Model for Therapeutic Testing against Multidrug-Resistant Pseudomonas aeruginosa Strains'. Together they form a unique fingerprint.

Cite this